Marvell Technology (MRVL) announced an interesting deal earlier this month, a transaction which warrants an update on the investment thesis on the company. The company has acquired some long-term promising technologies, and while Aquantia (AQ) will not add meaningfully to sales, let alone add to the bottom line, potential synergies look rather compelling.
I like deal-making efforts in capital and R&D-heavy industries, yet believe that Marvell still has to deliver on the full synergies from the Cavium deal, as the market setback has limited the actual realisation of the promise of that deal.